Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 196  
This article has been cited by
1Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
Ruben Mujica-Mota,Jo Varley-Campbell,Irina Tikhonova,Chris Cooper,Ed Griffin,Marcela Haasova,Jaime Peters,Stefano Lucherini,Juan Talens-Bou,Linda Long,David Sherriff,Mark Napier,John Ramage,Martin Hoyle
Health Technology Assessment.2018;22(49)1
2Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China
Lei Xu,Qingle Meng,Xiaochen Yao,Rui Yang,Pengjun Zhang,Rushuai Li,Feng Wang
Applied Radiation and Isotopes.2022;179(49)109975

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal